Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

5.6%

1 terminated/withdrawn out of 18 trials

Success Rate

93.8%

+7.2% vs industry average

Late-Stage Pipeline

33%

6 trials in Phase 3/4

Results Transparency

0 of 15 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4

3(30.0%)

Phase 3

3(30.0%)

Phase 2

3(30.0%)

N/A

1(10.0%)

10Total

Phase 4(3)

Phase 3(3)

Phase 2(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials

NCT03042754Not ApplicableActive Not Recruiting

Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals

Role: collaborator

NCT01634477Completed

Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study

Role: collaborator

NCT03731559Phase 2Recruiting

Efficacy, Safety and Pharmacokinetics of DTG with RIF

Role: collaborator

NCT01634607Completed

Bone Health and Vitamin D Status

Role: collaborator

NCT00476853Phase 2Completed

Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy

Role: collaborator

NCT01815255Completed

TDF Long Term Study

Role: collaborator

NCT02415985Phase 2Completed

Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly

Role: collaborator

NCT01328275Completed

Progress Adult Study

Role: collaborator

NCT01328288Completed

Progress Pediatric Study

Role: collaborator

NCT01307124Phase 3Completed

Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)

Role: collaborator

NCT01899157Completed

Nutritional Status Among naïve HIV Infected Patients and HIV Infected Patients Receiving Highly Active Antiretroviral Therapy

Role: collaborator

NCT01189695Phase 4Completed

Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure

Role: lead

NCT00483054Phase 3Completed

Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin

Role: lead

NCT01014481Phase 4Terminated

Appropriate Timing of HAART in Co-infected HIV/TB Patients

Role: lead

NCT01002898Phase 3Completed

Ritonavir-boosted Lopinavir Monotherapy

Role: lead

NCT01044810Completed

Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity

Role: lead

NCT00703898Phase 4Completed

Durability of Nevirapine-Based Antiretroviral Regimen

Role: lead

NCT00309582Completed

Nevirapine Levels and Fluconazole

Role: lead

All 18 trials loaded